Nigel Horscroft DPhil

Dr Nigel Horscroft is Area Head for Molecular Therapy at CureVac AG. Dr Horscroft has a BSc in Applied and Industrial Biology from London South Bank University and received his DPhil in Biochemistry from Oxford University where he studied Bluetongue Virus (BTV) replication at the NERC Institute of Virology and Environmental Microbiology. He then joined the Department of Neurology at the University of California – Irvine for post-doctoral studies on Borna Disease Virus (BDV) and infectious models of neurodevelopmental disorders.

Following his post-doctoral studies, Dr Horscroft remained in California and transitioned to the industry when he joined ICN Pharmaceuticals, which later became Valeant Pharmaceuticals. He returned to the UK to join Pfizer Global Research and Development in Sandwich and headed a variety of discovery projects. He then took on the role of Head of Research at Pike Pharma in Zurich, Switzerland. In 2012 Dr Horscroft joined CureVac in Tubingen, Germany.